A5 Secondary Metabolites · Depside · Evernia prunastri

Evernic Acid Natural Antioxidant Line

Isolated from Evernia prunastri and tested in DPPH and superoxide anion scavenging assays in our 2022 comparative study, then carried into the 2023 multi-compound panel. Clear positioning for cosmetic and nutraceutical antioxidant discovery.

Book a 30-minute discovery call Request the data package

Evidence: Peer-reviewed 2022 & 2023
Stage: Pilot-ready · licensing open
Indicative: € 4 000 – 20 000negotiable by scope and application

Scientific summary

Evernic acid is isolated from Evernia prunastri, collected and voucher-determined in Slovakia. It was characterised by NMR and tested in DPPH and superoxide anion scavenging assays in our 2022 comparative study, and included in the 2023 multi-compound screening panel.

Commercial positioning

Of the compounds in this line, evernic acid has the clearest fit with cosmetic and nutraceutical discovery programmes: a well-defined natural source, a documented isolation route, and antioxidant data generated in the same laboratory as the rest of the panel, so cross-compound comparison is internally consistent.

Applications

Natural antioxidant discovery
Cosmetic active screening
Nutraceutical evaluation
Antiproliferative panel member

Assays & readouts available

DPPH free-radical scavenging
Superoxide anion scavenging
2D and 3D viability
NMR structural confirmation

Specification

Compound class	Didepside (lichen secondary metabolite)
Biological source	Evernia prunastri
Evidence status	Published evidence (in vitro), two independent studies
Publications	Elečko J et al., Plants 2022;11(8):1077 · Kello M et al., Plants 2023;12(3):611
Typical pilot	Bioactivity pilot 4–8 weeks
Deliverables	Isolated material, assay data, technical report
Engagement	Feasibility scan · pilot · licensing
Indicative price	€ 4 000 – 20 000, negotiable by scope and application

Cosmetic and food applications are regulated separately in each market. We supply the scientific data; ingredient status, safety dossiers and claims remain the responsibility of the partner placing the product on the market.

What happens next

Book a call or send an inquiry. Tell us the target, the application and the timeline.
We answer within three working days — including when the answer is that we cannot help.
NDA before disclosure, if you need one. Tick the box on the form.
Feasibility scan or pilot proposal with a defined scope, deliverable and price.

Book a 30-minute discovery call Send an inquiry

Common questions

How does an engagement start?

With a free 30-minute discovery call. We establish whether there is a fit and what the right next step is. Nothing is committed at that point.

Can we sign an NDA before we describe our project?

Yes. Tick the NDA box on the inquiry form and we arrange it before any disclosure.

Are the prices on this site binding?

No. They are indicative ranges so that you can size a project before contacting us. Final terms are negotiated per scope.

How quickly do you reply?

Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

What happens if you cannot help?

We say so, early, and where we can we point you to someone who can. A negative feasibility answer delivered quickly is a useful result.

Related in Secondary Metabolites

A1Lead compound

Depside · Umbilicaria hirsuta

Gyrophoric Acid Platform

The best-characterised compound in the portfolio. Published work reports ROS production, apoptosis and modulation of Akt, Erk1/2 and p38 MAPK in HeLa cells, with a validated isolation protocol giving high-purity material.

Evidence: Peer-reviewed 2019 · mechanistic dataset
Stage: Pilot-ready · licensing open
Indicative: € 8 000 – 35 000negotiable by scope and application

View details Discuss this

Depsidone · Hypogymnia physodes

3-Hydroxyphysodic Acid Antioxidant Line

The strongest radical scavenger in our comparative metabolite study — and the comparison was made per mole rather than per unit weight. That distinction matters when you translate a screening result into a formulation dose.

Evidence: Peer-reviewed 2022 · DPPH + superoxide
Stage: Pilot-ready · licensing open
Indicative: € 5 000 – 25 000negotiable by scope and application

View details Discuss this

Depside · Reference metabolite

Atranorin Bioactivity Line

A widely cited lichen compound with repeatedly published bioactivity, included in both of our screening studies. A dependable reference compound and panel anchor for antiproliferative, antioxidant and antimicrobial work.

Evidence: Peer-reviewed 2022 & 2023
Stage: Pilot-ready · licensing open
Indicative: € 4 000 – 22 000negotiable by scope and application

View details Discuss this

Tell us what you are trying to achieve.

A free 30-minute call establishes whether there is a fit and what the right next step is. Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

Book a 30-minute discovery call Send an inquiry instead